Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations†
References (29)
- et al.
The impact of oral contraception on vulvovaginal candidiasis
Contraception
(1995) - et al.
A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis
Am J Obstet Gynecol
(1990) - et al.
Torulopsis glabrata vaginitis
Obstet Gynecol
(1995) - et al.
Single oral dose fluconazole compared with conventional topical therapy of Candida vaginitis
Am J Obstet Gynecol
(1995) - et al.
Establishing the cause of symptoms in women in a family practice
JAMA
(1984) - et al.
Candida vaginitis
Postgrad Med J
(1979) - et al.
Risk factors in vulvovaginal candidiasis: a case-control study among college students
Epidemiology
(1996) - et al.
Sexual transmission of Candida
Obstet Gynecol
(1987) - et al.
Recurrent vulvovaginal candidiasis: results of a cohort study of sexual transmission and intestinal reservoir
J Reprod Med
(1992) - et al.
Sexual behavior in women with repeated bouts of vulvovaginal candidiasis
Eur J Epidermiol
(1995)
Epidemiology of vulvovaginal candidiasis: risk factors
Am J Public Health
(1990)
Effect of recent sexual activity and use of diaphragm on vaginal flora
Clin Infect Dis
(1994)
Risk factors for Candida vulvovaginitis
Obstet Gynecol Surv
(1992)
Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections
J Infect Dis
(1996)
Cited by (535)
Factors associated with Trichomonas vaginalis infection in reproductive-aged women attending cervical screening in southeast of Brazil
2023, Brazilian Journal of Infectious DiseasesHigh diversity of yeast species and strains responsible for vulvovaginal candidiasis in South-East Gabon
2023, Journal of Medical MycologyCopper- and iodine-doped nanozymes with simulated enzyme activity and efficient antifungal activity against Candida albicans
2023, Biochemical Engineering JournalSuperficial fungal infections
2023, Molecular Medical Microbiology, Third Edition
- †
This consensus conference on vulvovaginal candidiasis was underwritten through an unrestricted educational gift from Pfizer, Inc., US Pharmaceuticals Group.
Presented at the consensus conference, “Vulvovaginal Candidiasis—A Contemporary Approach to Recognition and Management,” Orlando, Florida, April 25–26, 1996.
Copyright © 1998 Published by Mosby, Inc.